11

CORPORATE

PRESENTATION

November 2016

22

Company Overview

7 key markets

Growth marketsMature markets

China

#1Malaysia

#1Indonesia

#1Philippines

#1Singapore

#2India

#2Hong Kong

# Market share

Source: United Nations, Department of Economic and Social Affairs

Incorporated in 2001

The first cord blood bank to be set up in

Singapore and amongst the first in Asia

15 years of cord blood banking

experience as well as a successful track

record of cord blood releases for

transplants and therapeutic applications

Listed in Mainboard of Singapore

Exchange

Presence and facilities in 9 countries

Presence through associate(s) and sub-

licensing partner(s) and marketing

agent(s): Thailand (Thai Stemlife),

Myanmar and China

Our mission:

We are a consumer healthcare company

that serves the needs of the mother and

child. We deliver the highest of quality

standards in service and product offerings.

We maximise all stakeholders’ value by

engaging all employees to enable the

Company to achieve its fullest potential.

Myanmar

Marketing AgentSub-licensing

Partner

Associate

Thailand

33

Company Overview

Collection at birth, processing,

testing, cryopreservation and storage

of stem cells from the umbilical cord

blood – Haematopoietic Stem

Cells (HSCs)

6 products and services offering

Cord Blood Banking

Collection, processing, testing,

cryopreservation and storage of the

umbilical cord lining - Mesenchymal

stem cells (MSCs) and Epithelial

stem cells (EpSCs)

Patented technology – Exclusive licensing from CellResearch Corporation

Umbilical Cord Lining Banking

Catered for newborns, MetaScreen

detects as many as 106 metabolic

disorders

Non-invasive and advanced technology

testing on urine specimens

Metascreen: Non-invasive Urine based Metabolic Screening

Banking Diagnostics

Catered for expectant women in their 1st

trimester

Analyses cell free fetal DNA in mother’s

blood to detect fetal chromosomal

abnormalities using whole genome

sequencing

iGene: Non-Invasive Prenatal Testing (NIPT)

Simple and non-invasive detection of

vision problems in children as early as 6

months to 6 years old, for early

intervention.

Eyescreen: Paediatric Vision Screening

Collection, processing, testing,

cryopreservation and storage of the

umbilical cord tissue (Wharton’s

Jelly) – MSCs

Processed using in-house technique

for cell extraction and expansion.

Umbilical Cord Tissue (Wharton’s Jelly) Banking

44

Singapore Hong Kong India Philippines Indonesia

Top 1 Cordlife HealthBaby LifeCell Cordlife Cordlife

Top 2 StemCord Cordlife CryoBanks StemCord* BabyBanks*

Top 3 -- CryoLife Cordlife Medical City StemCord*

Total # of Companies

2 6 11 5 5

62%

91%

69%

98%

85%

38%

9%

31%

2%

15%

0%

10%

20%

30%

40%

50%

60%

70%

80%

90%

100%

Singapore Hong Kong(China)

India Philippines Indonesia

Top 3* Others

Less concentration in India due to the larger number of companies

Cordlife in market leader banks in 3 markets & amongst top 3 in 2 markets

Source: Deloitte & Touche Financial Advisory Services Limited report,10 April 2013

Top 3 banks represent 62% of market share in each country

Positioned to capture Asian growth

55

Top 3 private cord blood bank

player in each key market

Market share leadership in

each jurisdiction

Strong recurring cashflows

from high penetration rates

in each market

Higher profit margins from

economies of scale

Multiple product offerings

utilizing the same platform

Our Vision

Where

are we

now?

No.1consumer healthcare

player in Asia catering to

the mother & child segment

Our target

Increase penetration

Strategic partnerships

New service offerings

Focus on core competencies

Expand in the region

Unlock network value and synergies

Investments and marketing

efforts necessary to:

66

Cordlife Singapore’s Achievements

AABB

accreditation since

2005

Reaccreditation

audits: 2008 | 2009 |

2011 | 2013 | 2015

Ministry of Health

license

since 2002

Audits:

Once every 2 years

Good Distribution

Practice for

Medical Devices

since 2010

Cordlife subsidiariesCordlife Hong Kong:

• AABB accreditation

• ISO 9001:2008

• RCPA Quality Assurance Program

(participation)

Hong Kong Screening Centre Limited

• The College of American

Pathologists (certification)

Cordlife India:

• AABB accreditation

• ISO 9001:2008

• Drug Controller General India

certification

• The College of American

Pathologists (certfication)

Cordlife Philippines:

• ISO 9001:2008

• Department of Health registration

Cordlife Indonesia:

• ISO 9001:2008

• Ministry of Health certification

(DEPKES)

Stemlife Malaysia

• MOH certification

• ISO 15189

• The College of American

Pathologists (Certification)

FACT NetCord

since 2015

Commitment to Quality

77

Securities Investors

Association (Singapore)

16th SIAS Investors’

Choice Awards – Runner-

Up in Mid and Small

Category – Singapore

Corporate Governance

Award 2015

MyBB

Parent-Child

Favourite Cord

Blood & Umbilical

Cord Bank Co

Forbes Asia

200 Best Under a Billion

Brand name with proven record

Hong Kong

Economic Times

Baby & Kid

Brands Award

Capital Weekly

The Best

Performance

Company Award

Baby-Kingdom

Top 10 Family

Brand Award 2013

Frost & Sullivan

2016 Asian Pacific Stem

Cell Banking Company of

the Year Award

88

Andrew Ekaputra, PhDTechnical Director,

Innovation

Li Ming Ming, PhDDeputy Lab Director,

Group Lab Operations

Dr. Chiew Yoke FongMedical Director

Dr. Jennifer TeoMedical Director

Dr. Arvin C. FaundoCord Blood Bank Director

Dr. Cherie DalyMedical Affairs Consultant

Banking

Tang Kin Fai, PhDDeputy Lab Director,

Group Lab OperationsThet Hnin YiChief Financial Officer

Tan HuiyingGroup Director,

Quality & Ops.

Jamie WoonGroup Director,

Brand Devt. & Innovation

Stella LeeGroup Director,

Org. Devt.

Lin Aigu, PhDDeputy Lab Director,

Group Lab Operations

Scientific & Medical Advisors

Tomiko Kuhara, PhDScientific Advisor

Metabolic screening

Vrushali Joshi, PhDScientific Advisor

Metabolic screening

Corporate Team Members

Dr. Inez WongMedical Advisor

Paediatric Opthalmologist

Daniel Lim, PhDDeputy Technical Director,

Innovation

Dr Wong Chiang Yin

Group Chief

Executive Officer

Tan Poh Lan

Group Chief

Operating Officer

99

Group Structure

Cordlife

(Hong Kong)

100.0%

Shanghai

Cordlife

Biomedical

Research

100.0%

Cordlife Stem

Cell Technology

100.0%

Cordlife

Technologies

100.0%

CS Cell

Technologies

100.0%

SL

Diagnostics

Sdn. Bhd.

100.0%

Stemlife

89.88%

Cordlife Medical

Phils.

99.9%

Hong Kong

Screening Centre

67.0%

Cordlife

Sciences (India)

99.99%

PT. Cordlife

Persada

67.0%

Cordlife Group Limited

Malaysia China Hong Kong Singapore

Hong Kong Philippines India Indonesia

Thai

Stemlife

40.0%

Stemlife Pte.

Ltd.

100.0%

Stemlife

Logistics Sdn.

Bhd.

100.0%

Stemlife

Therapeutics

Sdn. Bhd.

100.0%

Stemlife

Properties

Sdn. Bhd.

100.0%

Thailand Singapore MalaysiaMalaysia Malaysia Malaysia

Singapore

1010

10

SERVICE PORTFOLIO

1111

Cord blood banking

Haematopoietic stem cells

• Collection of umbilical cord blood shortly after birth

• Isolation of haematopoietic stem cells: blood forming cells

• Standard therapy for over 80 conditions including certain cancers and blood related disorders such as leukaemia, lymphoma & neuroblastoma

• Potential therapy for many more diseases in clinical trials e.g. autism, cerebral palsy

1212

Cord lining banking

• Storage of umbilical cord epithelium & sub-epithelium• Rich in two stem cell types: Mesenchymal and Epithelial• Tissue repair, regenerative medicine & synergy with cord

blood• Patented technology and source material• Well over 650* clinical trials worldwide• Potential applications for heart attack, stroke, cartilage repair

and spinal cord injury.

*Source: clinicaltrials.gov – search term “umbilical cord”, accessed on 24 Nov 2016

1313

Newborn metabolic screening

• Inborn errors of metabolism (IEMs) are rare genetic disorders in which the body is lacking enzymes that maintain normal bodily metabolic function.

• Timely, non-invasive and accurate detection of more than 100+ Inborn Errors of Metabolism (IEMs) through urine specimen

• First in Cordlife’s pipeline of preventive healthcare services catering to the child

• Available in Hong Kong, Philippines and Indonesia

• Launching soon in Malaysia and Singapore

1414

• A safe and non-invasive paediatric eye screening that does not require any physical contact with the child or the need to deploy eyedrops to dilate the pupils.

• Able to detect up to 11 eye conditions such as Myopia (short-sightedness), and Strabismus (crossed eyes) and Amblyopia (lazy eye) in children as early as 6 months to 6 years old.

• Timely vision screening is recommended as being essential in infancy and childhood for the early detection and treatment of eye problems.

• Available in Singapore

Paediatric vision screening

1515

• Catered for expectant women in their 1st trimester

• Non-invasive prenatal testing (NIPT) is a relatively new type of screening that analysis cell free fetal DNA in mother’s blood to detect fetal chromosomal abnormalities with very high accuracy.

• Cordlife has partnered with iGene Diagnostics, a Singapore based molecular diagnostics company, to offer NIPT.

• Available in Singapore, Philippines and Indonesia.

Non-invasive Prenatal Testing

1616

16

FINANCIAL HIGHLIGHTS

1717

Financial Highlights

1818

3-Year Consolidated Statement of

Comprehensive Income(S$’mil) FY2014 FY2015 FY2016

Total revenue 49.1 57.6 59.6

Cost of sales (14.2) (17.6) (20.2)

Gross profit 34.9 40.0 39.5

Gross profit margin 71.1% 69.5% 66.2%

Other operating income 1.3 0.8 1.0

Selling and marketing expenses (12.2) (17.7) (19.0)

Administrative expenses (15.1) (17.3) (19.8)

Finance income 0.3 0.5 1.5

Finance costs (0.2) (0.2) (0.3)

Profit before income tax from

operations9.0 6.1 2.9

Non-core items * 22.8 27.1 10.4

Profit before income tax 31.8 33.2 13.3

Income tax expense (1.5) (1.1) (0.8)

Profit for the financial year 30.3 32.1 12.5

Note :

*Non-core items shown on next slide.

Numbers might not tally due to rounding differences.

1919

(S$’mil) FY2014 FY2015 FY2016

Share of results of associate (2.3) (0.4) (0.1)

Impairment loss on investment in associate - (2.6) -

Fair value gain/(loss) on investment properties 0.1 0.3 (0.2)

Fair value changes on financial asset

designated at fair value through P&L18.7 10.4 4.5

Fair value changes on derivative asset - 12.9 2.5

Gain on transfer from associate to financial

asset designated at fair value through P&L6.3 - -

Exchange differences - 4.7 6.0

Gain on sale of financial asset designated at

fair value through P&L- - 0.2

Gain on sale of convertible note - - 5.0

Remeasurement loss on previously held equity

interest in subsidiary- - (1.6)

Note repurchase expense - - (2.0)

Other expenses - - (2.4)

Finance income - 6.6 3.8

Finance costs - (4.6) (5.3)

Total non-core items 22.8 27.1 10.4

Note : Numbers might not tally due to rounding differences.

3-Year Consolidated Statement of

Comprehensive Income – Non-core

2020

3-Year Statement of Financial Position

(S$’mil) FY2014 FY2015 FY2016

Non-current assets

Investment in associate 16.8 13.5 -

Financial asset designated at fair value

through P&L50.5 60.9 -

Available-for-sale asset - - 4.2

Derivative asset - 38.0 -

Property, plant and equipment 8.4 9.6 13.3

Investment properties 4.8 3.8 9.2

Intangible assets 1.9 2.5 14.7

Deferred tax assets - - 0.2

Trade receivables 46.0 54.6 60.5

Other receivables 0.3 98.5 4.3

Total non-current assets 128.7 281.4 106.4

2121

(S$’mil) FY2014 FY2015 FY2016

Current assets

Cash and cash equivalents 32.6 15.7 69.7

Fixed deposits 11.8 12.3 53.4

Pledged fixed deposits 0.3 0.3 0.3

Short term investments 1.0 1.2 15.0

Trade receivables 12.9 15.3 21.0

Other receivables 1.1 4.2 2.0

Prepayments 1.7 1.7 1.7

Inventories 0.6 0.9 1.1

Total current assets 62.0 51.6 164.2

Current liabilities

Trade and other payables 8.9 11.6 13.5

Insurance contract liabilities - - 1.1

Deferred revenue 5.4 4.0 15.5

Tax payable 1.6 1.1 0.6

Interest-bearing borrowings 4.4 4.5 2.1

Total current liabilities 20.3 21.2 32.8

Net current assets 41.7 30.4 131.4

3-Year Statement of Financial Position

2222

(S$’mil) FY2014 FY2015 FY2016

Non-current liabilities

Other payables 0.1 1.3 0.1

Deferred revenue 20.5 23.6 24.7

Deferred tax liabilities 0.1 0.1 4.1

Interest-bearing borrowings 8.4 7.4 8.7

Notes payable - 117.5 67.4

Total non-current liabilities 29.1 149.9 105.0

Net assets 141.3 161.9 132.8

Capital and reserves

Share capital 96.7 96.7 96.7

Treasury shares (3.9) (9.9) (9.8)

Accumulated profits 51.3 78.6 54.7

Other reserves (2.6) (3.0) (10.8)

141.5 162.4 130.8

Non-controlling interests (0.2) (0.5) 2.0

Total equity 141.3 161.9 132.8

3-Year Statement of Financial Position

2323

3-Year Statement of Cash Flows

As at June 30 (S$’mil) 2014 2015 2016

Net cash flows generated

from/(used in) operating activities

3.7 (3.4) (4.4)

Net cash flows (used in)/from

investing activities

(9.6) (115.1) 153.3

Net cash flows from/(used in)

financing activities

30.6 101.7 (95.1)*

Note :

*Includes dividend paid of S$36.3 million, repurchase of notes of S$52.9 million, repayment of interest-bearing borrowings of

S$1.0 million and interest paid on notes of S$4.9 million.